PerkinElmer
check quantity

IVISense Tomato Lectin 680 Fluorescent Probe (TLectinSense)

IVISense Tomato Lectin 680 fluorescent probe (TLectinSense) is a NIR labeled macromolecule that targets the vasculature and enables imaging of blood vessels and angiogenesis.

This imaging probe labels endothelial cells and when used in conjunction with optical imaging systems such as PerkinElmer's industry leading IVIS® platform, can be used to non-invasively assess tumor vasculature in response to an anti-angiogenic drug, or to assess vascular burden as another biological consideration.

For research use only. Not for use in diagnostic procedures.

Part Number
List Price
Your Price
Quantity
NEV10060
672.00 USD
 
more
Buy Now

Please enter valid quantity

Please log in to add favorites.

NULL OR EMPTY CART

Overview

The protein tomato (L. esculentum) lectin is widely used for vascular labeling because the protein has a high binding affinity for glycoprotein N-acetylglucosamines on the surface of vascular endothelial cells.

IVISense Tomato Lectin 680 is a near-infrared fluorescent imaging probe that is comprised of the tomato lectin protein and a near-infrared fluorophore. This imaging probe targets the vasculature and enables imaging of blood vessels and angiogenesis. It was designed and optimized for use in living animals for assessing vascularity in vivo and in real-time, without termination of mice, excision and processing of the tissue.

Tumors induce significant blood vessel development in order to support their aggressive growth and progression. The extensive and disordered nature of tumor vasculature impairs drug delivery and efficacy. Therefore, destroying the tumor vasculature and/or inhibiting neo-vascularization have become well-accepted and proven cancer treatment strategies. IVISense Tomato Lectin 680 targets the surface of vascular endothelial cells and can be used for quantitation of vascular burden across different tumor cell lines.

Specifications

Fluorescent Agent Type Targeted
Optical Imaging Classification Fluorescence Imaging
Product Brand Name IVISense
Quantity in a Package Amount 1.0 Units
Shipping Condition Blue Ice
Therapeutic Area Angiogenesis, Oncology/Cancer
Unit Size 1 Vial (10 doses)
Wave Length 680 nm
Resources, Events & More
  • All

Ebook

In Vivo Imaging Solutions eBook

Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.

PDF 4 MB

Flyer

Best Practices for Designing An Effective In Vivo Fluorescence Imaging Study

Fluorescence molecular imaging is the visualization of cellular and biological function in vivo to gain deeper insights into disease processes and treatment effects. Designing an effective study from the beginning can help save time and resources.

Learn about several important best practices, from proper probe selection to study design to imaging technique tips and tricks needed to generate meaningful biological information from your in vivo fluorescence imaging studies.

PDF 507 KB
TLectinSense™ 680 (Product Sheet)

The protein Tomato (L. esculentum) lectin is widely used for vascular,labeling, because the protein has high binding affinity for glycoprotein N-acetylglucosamines on the surface of vascular endothelial cells. The TLectinSense agent is a near-infrared fluorescent imaging probe designed and optimized for use in living animals. One of the gold standard,methods for vascular mapping ex vivo, is now enabled for use in vivo.

PDF 1 MB

Poster

Targeted in vivo imaging of tumor vasculature using a near infra-red labeled tomato lectin agent

Tumor neo-vasculature, characterized by the development of abnormal, leaky and tortuous blood vessels, represents a key target for cancer imaging and therapy. Among the various recognized tools for measuring microvessel density is tomato (Lycopersicon esculentum) lectin, a single polypeptide glycoprotein that binds to sugar-containing proteins present on the endothelium. The aim of this study was to develop a near infra-red tomato lectin imaging agent to non-invasively assess tumor vasculature in vivo. Conjugation of the near infra-red fluorophore VivoTag 680XL (epsilon=210,000/M/cm; abs/em max 665/688 nm) to tomato lectin was carried out by addition of the fluorophore in a DMSO solution to lectin in aqueous sodium bicarbonate. Yields of greater than 95% were achieved, based on absorbance, with a typical loading of 2 dyes per lectin. The resulting agent, TLectinSenseTM 680 (TL680), preferentially labeled primary human umbilical vein endothelial cells. Specificity of the binding was validated by control experiments using free dye and competitive blockade with excess unlabeled tomato lectin. In vivo, non-invasive, real-time imaging and quantification of tumor neo-vasculature was performed in two models: matrigel plugs containing bFGF, VEGF and heparin injected into the flank of SKH-1 mice and nude mice bearing Lewis Lung Carcinoma tumors. Using Fluorescence Molecular Tomography (FMT®) 6 hours after TL680 (4 nmoles) intravenous injection, tumor endothelium-associated fluorescence was detected in matrigel plugs and this...

PDF 1007 KB

Technical Note

TlectinSense 680 (Protocol)

Protocol for TlectinSense 680 Targeted Fluorescent In Vivo Imaging Agent

PDF 257 KB

White Paper

The Role of In Vivo Imaging in Drug Discovery and Development

The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.

PDF 547 KB